Revolution Medicines (RVMD) Stock Analysis
This is a peer-relative look at Revolution Medicines (RVMD): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | RVMD |
|---|---|
| Name | Revolution Medicines, Inc. |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology |
| GICS Sub-Industry | Biotechnology |
| Market Capitalization | 41.59 billion USD |
| Currency | USD |
| Exchange | Nasdaq |
| Listing Date | February 13, 2020 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| Total Return (1Y) | 224.80% | 24.62% |
| Total Return (3Y, Annualized) | 114.71% | 20.37% |
| Total Return (5Y, Annualized) | 43.47% | -4.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 68.29% | 66.36% |
| Beta (5Y) | 1.42 | 0.93 |
| Max Drawdown (5Y) | -55.71% | -80.19% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 3.23 | 0.36 |
| Sortino Ratio (1Y) | 6.92 | 0.58 |
Profitability
ROE (TTM)
Revolution Medicines (RVMD) has negative ROE of -93.56%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-93.56%
Group distribution
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- RVMD
- -93.56%
- Min
- -167.77%
Largest peers
- LLY
- 86.02%
- NVS
- 24.33%
- AZN
- 22.57%
- JNJ
- 20.02%
- MRK
- 5.06%
- RVMD
- -93.56%
- ABBV
- --
Net Margin (TTM)
Revolution Medicines (RVMD) keeps 0.00% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- Max
- 18.05%
- Q3
- 4.78%
- RVMD
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Largest peers
- LLY
- 31.90%
- AZN
- 17.68%
- NVS
- 17.49%
- JNJ
- 16.20%
- ABBV
- 15.67%
- MRK
- 3.64%
- RVMD
- 0.00%
Operating Margin (TTM)
Revolution Medicines (RVMD) has negative operating margin of -188.88%. Core operations were loss-making before interest and taxes over the trailing period.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-188.88%
Group distribution
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- RVMD
- -188.88%
- Min
- -207.40%
Largest peers
- LLY
- 53.66%
- ABBV
- 39.59%
- MRK
- 35.22%
- NVS
- 34.27%
- AZN
- 29.57%
- JNJ
- 25.74%
- RVMD
- -188.88%
Profitability Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| ROE (TTM) | -93.56% | -26.66% |
| ROA (TTM) | -32.13% | -12.50% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -188.88% | 0.00% |
| Gross Margin (TTM) | 0.00% | 37.87% |
Growth
Revenue Growth
No usable revenue growth is available for Revolution Medicines (RVMD) this period, so the top-line momentum read is skipped.
EPS Growth
No usable EPS growth is available for Revolution Medicines (RVMD) this period, so the earnings-momentum read is skipped.
Growth Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | -- | 11.45% |
| Revenue Growth (3Y CAGR) | -- | 9.94% |
| EPS Growth (YoY) | -- | 4.28% |
| EPS Growth (3Y CAGR) | -- | 4.17% |
Financial Strength
Current Ratio (MRQ)
Revolution Medicines (RVMD) has current ratio of 8.36, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.36
Group distribution
- Max
- 25.13
- Q3
- 12.13
- RVMD
- 8.36
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Largest peers
- RVMD
- 8.36
- LLY
- 1.39
- MRK
- 1.35
- JNJ
- 1.02
- AZN
- 1.01
- NVS
- 0.88
- ABBV
- 0.87
Debt / Equity (MRQ)
Revolution Medicines (RVMD) has debt-to-equity ratio of 0.50, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.50
Group distribution
- Max
- 1.42
- Q3
- 0.65
- RVMD
- 0.50
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Largest peers
- NVS
- 1.29
- LLY
- 1.23
- MRK
- 1.20
- AZN
- 0.66
- JNJ
- 0.55
- RVMD
- 0.50
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 8.36 | 5.52 |
| Debt / Equity (MRQ) | 0.50 | 0.15 |
| Net Debt / EBITDA | -- | 1.08 |
Dividends
Dividend Yield (TTM)
Revolution Medicines (RVMD) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.88%
- ABBV
- 2.40%
- MRK
- 2.29%
- JNJ
- 1.94%
- AZN
- 1.73%
- LLY
- 0.49%
- RVMD
- 0.00%
Dividend Payout Ratio (TTM)
Revolution Medicines (RVMD) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 343.43%
- ABBV
- 117.35%
- NVS
- 90.46%
- JNJ
- 80.12%
- AZN
- 45.38%
- LLY
- 21.71%
- RVMD
- 0.00%
Dividend Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
No usable P/E ratio is available for Revolution Medicines (RVMD) this period, so the trailing-earnings valuation read is skipped.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RVMD
- --
Largest peers
- MRK
- 148.21
- ABBV
- 50.05
- LLY
- 43.95
- JNJ
- 41.92
- NVS
- 31.02
- AZN
- 26.37
- RVMD
- --
P/S Ratio (TTM)
Revolution Medicines (RVMD) trades at 210.51 on P/S ratio, above the industry benchmark range. The stock is being valued at an unusually rich price per dollar of trailing revenue.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
210.51
Group distribution
- RVMD
- 210.51
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
Largest peers
- RVMD
- 210.51
- LLY
- 13.95
- ABBV
- 7.80
- JNJ
- 6.69
- MRK
- 5.37
- NVS
- 5.35
- AZN
- 4.63
P/B Ratio (MRQ)
Revolution Medicines (RVMD) trades at 17.31 on P/B ratio, above the industry benchmark range. Investors are putting an unusually rich price on each dollar of book equity relative to peers.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.31
Group distribution
- RVMD
- 17.31
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Largest peers
- LLY
- 29.96
- RVMD
- 17.31
- NVS
- 8.25
- JNJ
- 8.16
- MRK
- 8.06
- AZN
- 5.59
- ABBV
- -112.34
Valuation Metrics
| Metric | Current stock: RVMD | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | -- | 26.69 |
| P/S Ratio (TTM) | 210.51 | 7.30 |
| P/B Ratio (MRQ) | 17.31 | 3.25 |
| Free Cash Flow Yield (TTM) | -2.13% | -1.66% |